Commissioner of health directed to study and report on activities to support innovations in cell and gene therapy to treat rare diseases, report required, and money appropriated.
Expressing support for the Texas Health and Human Services Commission's application to the Cell and Gene Therapy Access Model through the Centers for Medicare and Medicaid Services and its Center for Medicare and Medicaid Innovation.
Hospital reimbursement for certain biological products to treat rare diseases provisions modifications
An Act Requiring Medicaid Coverage For Fda-approved Gene Therapies To Treat Sickle Cell Disease.
An Act Establishing An Advisory Council On Chimeric Antigen Receptor T-cell Therapy And Other Gene Therapies.
Rare diseases; establish Rare Disease Task Force and establish insurance coverage integrity for rare disease therapies.
An Act Requiring Medicaid Coverage For Bone Marrow And Stem Cell Transplants And Fda-approved Gene Therapies To Treat Sickle Cell Disease.
A resolution expressing support for the designation of September 2025 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases